
A randomized controlled trial of an electronic health record (EHR) alert reporting individual heart failure (HF) patients’ one-year mortality risk did not result in significant differences in clinical outcomes or clinician decision-making. Dr. Tariq Ahmad, Associate Professor of Medicine at Yale University, and the primary investigator of the trial, presented the results of the Risk Evaluation and its Impact on Clinical Decision Making and Outcomes in Heart Failure (REVEAL-HF) Trial during the American Heart Association Scientific Sessions 2021 Late Breaking Science Session on improvement of care delivery through digital health and automated data.
HF risk prediction tools are plentiful, but rarely used clinically, as they are not easily built into clinician workflow. Their effects on clinical decision-making and outcomes have never been evaluated in a randomized process. Practitioners caring for hospitalized HF patients at four Yale University-affiliated hospitals were randomized to receive, or not receive, a visual EHR alert highlighting a patient’s one-year risk of mortality. The primary outcome was a composite of all-cause mortality and re-hospitalization.
#AHA21 Reveal-HF RCT by @yaleHFdoc
‼️EHR alert displaying 1y☠️risk
🖥️>3000 HF patients
🚫No changes in outcomes
🚫Consistent across subgroups@jeanlucvachiery @coconnormd @DukeHFDoc @HFA_President @HeartBobH @SABOURETCardio @AnastasiaSMihai pic.twitter.com/FUajMBpkt4— Andreas Gevaert (@AndreasGevaert) November 14, 2021